Search Results
Aug 03, 2026, 09:00 ET BOTOX® (toxina botulínica A) recebe aprovação da Anvisa para uso no músculo platisma
placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025 Feb;92(2):285-291.Trindade de Almeida A, De Boulle K, Lorenc ZP, Carruthers J, Braz A, Bertossi D, Dimitrijevic E, Shimoga S, Hopfinger R. Platysma Prominence: Review and Expert Analysis of Clinical Presentation, Burden, and Treatment Considerations.
More news about: Allergan
Aug 03, 2026, 09:00 ET Ritual's Essential Prenatal--the #1 best-selling prenatal backed by its own human clinical trial--is now available at Costco locations nationwide.
needs before and during pregnancy, including Omega-3 DHA, Choline, and bioavailable Methylated Folate to support fetal brain development, as well as D3, K2, Magnesium, and Boron to support bone health.* Plus, it features patented nutrient-delivery technology with a nested, delayed release capsule, and
More news about: Ritual
Aug 03, 2026, 09:00 ET Rennova® apresenta soluções para compor protocolos integrados e individualizados para pacientes com lipedema
TechA Rennova® Tech é a marca de tecnologia da Rennova®, focada em redefinir o mercado de equipamentos estéticos. Nascida da liderança em P&D 100% nacional, design e excelência em qualidade, a marca oferece um ecossistema completo de soluções para o mercado estético, sob o conceito de "Liberdade
More news about: Rennova
Aug 03, 2026, 08:55 ET Guidewire Introduces Qusar Release to Help Insurers Build and Control AI Agents
P&C insurers.We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications
More news about: Guidewire Software
Aug 03, 2026, 08:55 ET Guidewire Introduces Qusar Release to Help Insurers Build and Control AI Agents
P&C insurers.We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications
More news about: Guidewire Software
Aug 03, 2026, 08:43 ET Los Angeles Pop Artist ALYA Finds Hope in New Cinematic Single 'Believer'
connecting audiences through themes of hope, humanity, and empowerment. She has collaborated with artists including Eric Clapton, Erica Campbell, and D Smoke, and her ongoing "Hope" project, including Hope: The Sequel, has grown into a movement centered on kindness and collective good."Believer"
More news about: ALYA
Aug 03, 2026, 08:42 ET Seoul National University of Science and Technology Develops an AI Framework for Long-Term Bridge Damage Monitoring
Monitoring on April 27, 2026.This study enables long-term monitoring by combining artificial intelligence with three-dimensional (3D) bridge reconstruction. The 3D model of the bridge is built using images captured during the initial inspection. Images from subsequent inspections are then automatically
More news about: Seoul National University of Science and Technology
Aug 03, 2026, 08:34 ET Sonorous Neurovascular Achieves First Canadian Enrollment in B-SILENT Study, Expanding Global Momentum
www.sonorousnv.com.Contact:James D. Nonato, Vice PresidentSonorous NeurovascularEmail: [email protected] Phone:
More news about: Sonorous Neurovascular
Aug 03, 2026, 08:32 ET FAIR Health NSA and Allowed Data Products May Be Introduced in IDR Proceedings to Support Offers, and IDR Entities May Consult FAIR Health Data to Validate Party Submissions
year. A national Qualified Entity certified by CMS, FAIR Health also receives all claims for individuals enrolled in traditional Medicare Parts A, B and D. As a testament to its reliability and objectivity, FAIR Health's data products—including pricing benchmarks and custom analytics—are widely used by commercial
More news about: FAIR Health
Aug 03, 2026, 08:30 ET Esquire Financial Holdings, Inc. Completes Acquisition of Signature Bancorporation, Inc. on August 1, 2026
name "Signature, a division of Esquire Bank" (the "Division"). Michael G. O'Rourke will serve as President of the Division. Kevin P. Bastuga and Bryan D. Duncan will each serve as Executive Vice Presidents of the Division.Michael G. O'Rourke, President of Signature, a division of Esquire Bank, added,
More news about: Esquire Financial Holdings, Inc.
Aug 03, 2026, 08:17 ET Genezen and the Raiden Science Foundation Announce Partnership for AAV9 Gene Replacement Therapy for UBA5 Clinical Trial
gene replacement therapy for UBA5 disorder. This partnership marks a major milestone for RSF, moving its UBA5 gene therapy program from four years of R&D into clinical manufacturing and one step closer to the first-in-human clinical trial for this devastating disorder.
More news about: Genezen
Aug 03, 2026, 08:01 ET NextPlat to Release Second Quarter 2026 Results on Thursday, August 13, 2026
https://viavid.webcasts.com/starthere.jsp?ei=1770457&tp_key=6a139162d1Please call the conference telephone number 5-10 minutes prior to the start time.
More news about: NextPlat Corp.
Aug 03, 2026, 08:00 ET PENSKE INVESTIGATION ALERT: Kaskela Law Firm is Investigating Penske Automotive Group, Inc. (PAG) and Encourages PAG Stockholders to Contact the Firm
the company's shares and potentially shortchanges PAG investors.Penske Automotive shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at [email protected]
More news about: Kaskela Law LLC
Aug 03, 2026, 08:00 ET Unhappy With The $35.00 Per Share Buyout Price? Contact Kaskela Law to Discuss Your Legal Rights and Options with Respect to the Buyout - DSGR
securities laws in agreeing to the $35.00 per share buyout price from LKCM Headwater. DSG shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at [email protected],
More news about: Kaskela Law LLC
Aug 03, 2026, 08:00 ET Unhappy With The $14.25 Per Share Buyout Price? Contact Kaskela Law to Discuss Your Legal Rights and Options with Respect to the Buyout - UTZ
maintaining price targets for Utz shares well above the agreed-to buyout price.Utz shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at [email protected],
More news about: Kaskela Law LLC
Aug 03, 2026, 08:00 ET cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease
Graham Heap, MD, PhD joins as President, Research and Development (R&D), with responsibility for leading all the Company's research and development activities. Ezequiel Neimark, MD joins as Head of Clinical Development
More news about: cAMPfield Therapeutics
Aug 03, 2026, 08:00 ET Broadcom Inc. to Announce Third Quarter Fiscal Year 2026 Financial Results on Wednesday, September 2, 2026
develops, and supplies semiconductors and infrastructure software for global organizations' complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more
More news about: Broadcom Inc.
Aug 03, 2026, 08:00 ET Momcozy Launches The Lactation Line, for Free 24/7 Breastfeeding Support
DeepClean Bottle Washer (D8) was designed to reduce that burden by washing, sterilizing and drying multiple bottles and pump parts in a single cycle, while targeted water flow is engineered to reach narrow and difficult-to-clean areas. By reducing manual cleaning steps, the D8 helps simplify everyday
More news about: Momcozy
Aug 03, 2026, 08:00 ET Arbe to Present at Canaccord Genuity's 46th Annual Growth Conference
announced agreements and the risks and uncertainties described in "Cautionary Note Regarding Forward-Looking Statements," "Item 3. Key Information - D. Risk Factors" and "Item 5. Operating and Financial Review and Prospects" and in the Company's Annual Report on Form 20-F for the year ended December
More news about: Arbe
Aug 03, 2026, 08:00 ET Levi & Korsinsky LLP and Wohl & Fruchter LLP Announce Pendency and Proposed Settlement of Class Action Affecting Preferred Stockholders of Cedar Realty Trust, Inc.
settlement ("Settlement") of the Action with defendants Bruce J. Schanzer, Gregg A. Gonsalves, Abe Eisenstat, Steven G. Rogers, Sabrina Kanner, Darcy D. Morris, Richard H. Ross, and Sharon Stern ("Defendants"), Cedar Realty Trust, Inc. ("Cedar"), and Wheeler Real Estate Investment Trust, Inc. ("Wheeler",
More news about: Levi & Korsinsky, LLP and Wohl & Fruchter LLP
Aug 03, 2026, 08:00 ET Lipocine Appoints Michael J. Grissinger to Board of Directors
Johnson, Mr. Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was also a member of the Immunology R&D/Commercial leadership team for Johnson & Johnson's Worldwide Immunology Franchise. Prior to Johnson & Johnson, Mr. Grissinger spent 12 years at
More news about: Lipocine Inc.
Aug 03, 2026, 08:00 ET FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant
More news about: Acurx Pharmaceuticals, Inc.
Aug 03, 2026, 07:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
doi:10.1053/j.seminoncol.2021.02.003Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016;8(4):45. Published 2016 Apr 18. doi:10.3390/cancers8040045Muller M, Tougeron D. KRAS G12C inhibitors: also a new promising
More news about: Eli Lilly and Company
Aug 03, 2026, 07:30 ET Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
Res. 2003;15(Suppl 5):S91–S92.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.DiBenedetti DB, Nguyen D, Zografos L, et al. Adv Urol. 2011; 2011:282503.
More news about: Keenova Therapeutics
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
2025 reflect the recognition of portions of both the upfront payment and the IND milestone payment from the license agreement with Gilead.R&D expenses for the second quarter of 2026 were approximately $6.3 million, compared to approximately $5.6 million in the second quarter
More news about: Compugen Ltd.